The Native Antigen Company is part of LGC Clinical Diagnostics - Learn More

0 Items
Select Page

Humanised SARS-CoV-2 Antibodies

The Native Antigen Company now offers humanised, recombinant versions of its monoclonal anti-SARS-CoV-2 Spike antibodies. These antibodies have been tested against our range of Spike variants, showing differential binding affinities.

Humanised Antibodies

Humanised antibodies are antibodies from non-human species whose protein sequences have been modified to increase their similarity to human antibodies. When designing assays to qualify and quantify patient sera, humanised antibodies can therefore act as “truer” patient controls than their monoclonal equivalents from mice or rabbits. When developing human therapeutics, humanised antibodies are similarly needed due to the induction of off-target immune responses against antibodies from animal species.

Our Expanded Range

The Native Antigen Company offers five humanised, recombinant versions of its monoclonal Spike-specific SARS-CoV-2 antibodies. These antibodies have been tested against Spike proteins from a range of variants, showing differential binding affinities and neutralising ability:

Antibody Clone
Variant/Target
 
Wuhan-Hu-1
(Wild Type)
 
 
B.1.1.7
(Alpha)
 
 
501Y.V2
(Beta)
 
 
P.1/B.1.1.28
(Gamma)
 
 
B.1.617.1
(Kerala)
 
 
B.1.617.2
(Delta)
 
 
B.1.1.529
(Omicron)
 
 
DH6
 
 
Spike RBD (Neutralising)
 
 
Spike RBD (Neutralising)
 
 
Spike RBD (Neutralising)
 
 
Spike RBD (Neutralising)
 
 
Spike RBD (Neutralising)
 
 
Not determined
 
 
Not determined
 
 
CH1
 
 
Spike S1
 
 
Spike S1
(Non-RBD)
 
 
Spike S1
(Non-RBD)
 
 
Spike S1
(Non-RBD)
 
 
Spike S1
(Non-RBD)
 
 
Not determined
 
 
Not determined
 
 
CE5
 
 
Spike S1
 
 
Spike S1
(Non-RBD)
 
 
Spike S1
(Non-RBD)
 
 
Spike S1
(Non-RBD)
 
 
Spike S1
(Non-RBD)
 
 
Not determined
 
 
Not determined
 
 
HH10
 
 
Spike S1
 
 
Spike S1
(Non-RBD)
 
 
Spike S1
(Non-RBD)
 
 
Spike S1
(Non-RBD)
 
 
Spike S1
(Non-RBD)
 
 
Not determined
 
 
Not determined
 
 
EB5
 
 
Spike RBD (Neutralising)
 
 
No binding
 
 
No binding
 
 
No binding
 
 
Spike RBD
 
 
Not determined
 
 
Not determined
 

For more information on these antibodies, click the buttons below or get in touch with a member of our team:

See our Full Range

The Native Antigen Company provides an extensive range of reagents to support coronavirus R&D, including antigens, antibodies, receptors, enzymes, neutralisation kits and contract services.

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

2 + 4 =

The Role of Serology in Tracking COVID-19 Mutations

This article was originally published on Clinical Lab Products. As SARS-CoV-2 began its global proliferation in early 2020, scientists hastened to investigate its biology, develop diagnostic tests, and design candidate vaccines, marking one of the most...

Preparing for Disease Y: A Better Serological Toolbox

This article was originally published on Clinical Lab Manager. It’s been over a year since the World Health Organization (WHO) declared COVID-19 a pandemic. SARS-CoV-2 has since infected 200 million people, resulting in nearly 4 million deaths and substantial economic...

Keeping Up with the New SARS-CoV-2 Variant Nomenclature

If you’ve been struggling to make sense of SARS-CoV-2 variant nomenclature, you’re not alone. Due to the existence of multiple genomic sequence databases, various naming systems are in use for the rapidly growing range of SARS-CoV-2 variants of concern/interest. In a...

Making Sense of the SARS-CoV-2 Spike Mutations

Through much of 2020, SARS-CoV-2 accumulated mutations at a steady, yet unspectacular rate. However, as global cases approached 100 million by the end of the year, multiple variants began to emerge. Exhibiting more considerable genomic changes, some variants have...

D614G: Putting the Mutation in Perspective

Since the emergence of SARS-CoV-2, scientists have speculated about the risks of mutation and what this could mean for therapeutics and vaccines. In this blog, we explore the nature viral mutation, what is known about the D614G mutant of SARS-CoV-2, and introduce our...

The Endemic Coronaviruses and What They Might Tell us About COVID-19

While less-well known than some of their counterparts, the 229E, NL63, OC43, and HKU1 human coronaviruses are a significant cause of respiratory disease worldwide. The evolutionary histories and host associations of the endemic coronaviruses also provide important...

Q&A: An Insight Into COVID-19 Serology

During the course of the current coronavirus pandemic, we have all been aware of the urgent need for nucleic acid testing to identify people currently infected with SARS-CoV-2. The second form of testing needed are serological immunoassays, which can identify past...

A Q&A with David Flavell of Leukaemia Busters

In this blog, we speak with Dr. David Flavell about his scientific career, the legacy of Leukaemia Busters, and the recent impact that COVID-19 has had on his research.Tell me about your scientific background David. I was born in a seaside town called Southport in the...

Avoiding the Immunopathology Pitfalls of a COVID-19 Vaccine

In the second of a three-part series on COVID-19 vaccines, we explore the potential challenges in stimulating safe vaccine responses and outline the role that diagnostics will play in guiding their development.Rogue Responses Antibodies play a crucial role in...

Designing for Differentiation: Why We Need Highly Specific Diagnostics for a COVID-19 Vaccine

Assessment of vaccine-induced immune responses in clinical trials will require highly specific diagnostic assays to ensure safety. This blog was originally published on Clinical Lab Manager.The Vaccine Race Vaccines are the most effective means of preventing...

An Early Look at Vaccines for COVID-19

In the first of a three-part series on the design, immunology and manufacture of COVID-19 vaccines, we take an early look at the major technologies under development and weigh-up the challenges these vaccines will face in reaching late-phase clinical trials.Why We...

Why We Need Antigen and Antibody Tests for COVID-19

RT-PCR is the workhorse of viral diagnosis and has been invaluable in COVID-19 case confirmation and isolation guidance. However, while fast and sensitive, PCR suffers from some inherent drawbacks that limit it to diagnosis during the acute phase of infection. To...

Novel Coronavirus Antigens Now Available

The Native Antigen Company is now offering recombinant S1 and S2 glycoproteins for SARS-CoV-2 (Covid-19) in response to urgent demand. These reagents are suitable for use in basic research and the development of diagnostics and vaccines.These antigens have been...

Coronaviruses: The Next Disease X?

For much of their known history, the coronaviruses were regarded as relatively benign pathogens with little potential to cause human harm. However, the emergence of SARS and MERS in recent decades has brought coronaviruses into the global spotlight. In this blog we...